Because of the selection of CDK4/6 inhibitors now available in the first-line setting for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, providers now have the ...

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Actor Aruna Irani recently revealed she kept her breast cancer diagnosis private. While she initially avoided chemotherapy ...

University of Cambridge study shows how LLM GPT-4 can generate novel combinations of drugs not typically used to treat cancer ...

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Karin Pelka is the 2025 recipient of the AAAS Martin and Rose Wachtel Cancer Research Award for her work with these critical multicellular networks.

MacMillan has been named a Distinguished Scholar in the Princeton Branch of the Ludwig Institute for Cancer Research, which ...

BAMF Health in Grand Rapids has launched a study to identify markers for targeted breast cancer therapies using PET scans.